key: cord-0794283-2nte7ruv
authors: Yemane, Divora; Lu, Ivan; Tiahjono, Winson; Rubidoux, Lauren; Hussain, Abbas; Cancilla, John C.; Duggan, Erika; Shaner, Nathan C.; Nakanishi, Nobuki; Wang, Jiwu
title: Single-Domain SARS-CoV-2 S1 and RBD Antibodies Isolated from Immunized Llama Effectively Bind Targets of the Wuhan, UK, and South African Strains in vitro
date: 2021-02-16
journal: bioRxiv
DOI: 10.1101/2021.02.15.431198
sha: b0288b33c075a71e88d50abc2e1ee7a5252fbbae
doc_id: 794283
cord_uid: 2nte7ruv

The spreading of SARS-CoV-2 variants has become a major challenge of the current fight against the pandemic. Of particular concerns are the strains that have arisen from the United Kingdom (UK) and South Africa. The UK variant spreads rapidly and is projected to overtake the original strain in the US as early as in March 2021, while the South African variant appears to evade some effects of the current vaccines. Potential false-negative diagnosis using currently available antigen kits that may not recognize these variants could cause another wave of community infection. Therefore, it is imperative that antibodies used in the detection kits are validated for binding against these variants. Here we report that the nanoantibodies (nAbs in our terminology, also referred to as VHH fragments, single domain antibodies, nanobodies™) that we have developed for rapid antigen detection test bind the receptor binding domain (RBD) of the S1 protein from the original COVID-SARS-2 virus as well as those from the UK and South African variants. This finding validates our antibodies used in our assay for the detection of these major variant strains.

The spreading of SARS-CoV-2 variants has become a major challenge of the current fight against 23 the pandemic. Of particular concerns are the strains that have arisen from the United Kingdom 24 (UK) and South Africa. The UK variant spreads rapidly and is projected to overtake the original 25 strain in the US as early as in March 2021, while the South African variant appears to evade some 26 effects of the current vaccines. Potential false-negative diagnosis using currently available antigen 27 kits that may not recognize these variants could cause another wave of community infection.

Therefore, it is imperative that antibodies used in the detection kits are validated for binding 29 against these variants. Here we report that the nanoantibodies (nAbs in our terminology, also 30 referred to as VHH fragments, single domain antibodies, nanobodies TM ) that we have developed 31 for rapid antigen detection test bind the receptor binding domain (RBD) of the S1 protein from the 32 original COVID-SARS-2 virus as well as those from the UK and South African variants. This 33 finding validates our antibodies used in our assay for the detection of these major variant strains.

We immunized a llama by repeated injections of recombinant S1 and RBD proteins. Using our 37 nanoantibody (nAb) development pipeline that resulted in dozens of drug candidate nAbs over a 38 decade [1] , we isolated multiple families of anti-RBD nAbs that showed strong binding affinity and 39 specificity against the RBD of the clinical strain Wuhan-Hu-1. We then characterized the 40 properties of these nAbs through various experiments that will be published separately. We 41 further developed a prototype rapid antigen test in the format of lateral flow assay with these nAbs 42 using clinical samples before the spread of the current major variants.

The UK variant, also referred to as SARS-CoV-2 B.1.1.7 lineage, contains ~20 amino acid 45 changes in total, one of which is in the RBD (N501Y) and several in the N-terminus of the S1 

Nanoantibodies, on the other hand, bind their antigens through distinct mechanism than IgG 50 antibodies. With a size that is approximately 10x smaller than IgG, the VHH single-domain derived 51 nAbs can insert its epitope-contacting amino acids into crevices on their antigens [2] instead of 52 "wrapping around" exposed epitopes by a heavy chain/light chain arm pair of IgG, affording a 53 possibility that the epitope recognition of nAbs might be less affected by individual amino-acid 54 mutations of the variants than that of mAbs. In this report, we show that our nAbs indeed bind from BEI and conjugated to Spherotech particles before flow cytometry was performed. We tested 59 the binding ability of nAb1 and nAb2, representing two of several families of anti-SARS-CoV-2 nAbs that we isolated. We previously determined their dissociation constant (Kd) toward WT RBD 61 through serial dilutions as a measure of binding affinity and found that nAb1 and nAb2 showed 62 Kds between 6 nM to 15nM when conjugated to different fluorescent proteins. We then set to test 63 the binding affinities of nAb1 and nAb2 towards variant RBDs as described below. To facilitate 64 the detection of nAbs in the flowcytometry assay as well as our rapid antigen diagnostic kit, we 65 genetically fused each nAb with mNeonGreen, the brightest monomeric fluorescent protein that 66 we previously developed [3] . We also produced a genetic fusion protein that contains two nAb1 67 domains linked via a linker (referred to as nAb1 dimer).

As shown in Figure 1 , we found that both mNeonGreen-fused nAb1 and nAb2 bind to RBDs from 70 all three strains above the background binding to bovine serum albumin (BSA). Note that these 71 three RBDs when conjugated to the Spherotech beads as carrier particles have not been 72 normalized for quantitative cross-comparison, therefore we could not conclude relative binding 73 affinity for each RBD. More quantitative and direct comparison will be performed with additional 74 experiments. As a control, we used the monoclonal antibody CR3022, which was originally 75 isolated for its binding to the S protein of SARS-CoV [4] and crossreacts to SARS-CoV-2 S 76 protein. CR3022 we obtained from R&D Systems binds to the WT RBD but not to UK or South 77 African RBDs in our hand, despite the computational prediction that mutations on South African 78 RBD might minimally affect CR3022 binding [5] . Interestingly but not surprisingly, nAb1 dimer 79 binds all RBDs with affinity seemingly higher (after adjusting different fluorescent labelling) than 

The nAbs that bind to SARS-CoV-2 Wuhan RBD/S1 proteins were isolated by methods that we 99 described in detail [1] . Briefly, a llama was repeatedly immnunized with recombinant Wuhan RBD 100 and S1 proteins obtained from BEI Resources. Several weeks after the initial injection, the blood 101 from the llama was harvested and mRNAs isolated from an enriched lymphocyte population.

Reverse transcriptase (RT)-PCR was performed using a set of primers that specifically amplify 103 VHH domains and amplified cDNAs cloned into an M13 vector. Phage display based on enzyme-104 linked immunosorbent assay (ELISA) was performed in 96-well plates to isolate VHH cDNAs that 105 specificially bind to Wuhan RBD and S1 proteins. The positivie cDNAs are subcloned into an E.

coli expression vector for the production of RBD/S1 nAbs.

Flow cytometry using protein-conjugated beads. 

Modified Nanoantibodies 151 Increase Sensitivity in Avidin-Biotin Immunohistochemistry

The therapeutic potential of nanobodies

A bright 158 monomeric green fluorescent protein derived from Branchiostoma lanceolatum

Human monoclonal 162 antibody combination against SARS coronavirus: synergy and coverage of escape 163 mutants

Impact of South African 501.V2 166 variant on SARS-CoV-2 spike infectivity and neutralization. A structure-based 167 computational assessment

Structures and distributions of SARS-CoV-2 spike 171 proteins on intact virions

UK and South African strains via . The results presented in the left panel indicate 177 that S-nAb1 binds to Wuhan and UK RBPs, but not to South African RBP

South Africa) RBPs. The right panel of the figure shows 179 two control experiments. In control 1 (negative control), the anti-HA mAb alone resulted in low or 180 no binding to BSA-or RBP-conjugated beads

Control2 (SARS-CoV-2 mAb)